2021
SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain
Bayarri-Olmos R, Idorn M, Rosbjerg A, Pérez-Alós L, Hansen C, Johnsen L, Helgstrand C, Zosel F, Bjelke J, Öberg F, Søgaard M, Paludan S, Bak-Thomsen T, Jardine J, Skjoedt M, Garred P. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. The Journal Of Immunology 2021, 207: 878-887. PMID: 34301847, DOI: 10.4049/jimmunol.2100272.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCoronavirus Nucleocapsid ProteinsCOVID-19COVID-19 SerotherapyCOVID-19 VaccinesEnzyme-Linked Immunosorbent AssayHumansImmunizationImmunization, PassiveImmunoglobulin AImmunoglobulin GImmunoglobulin MMiceNeutralization TestsProtein DomainsReceptors, VirusSARS-CoV-2Spike Glycoprotein, CoronavirusConceptsPlaque reduction neutralization testReceptor-binding domainReduction neutralization testNeutralization testFull-length spike proteinSARS-CoV-2 transmissionSARS-CoV-2 receptor-binding domainViral neutralization testSARS-CoV-2Levels of AbsIgG titersVaccine strategiesAntibody responsePreclinical modelsConvalescent seraImmune responseMouse modelNeutralization potencyVirus neutralizationFull spikesImmunization strategiesMurine mAbsImmunization resultsSpike proteinELISA
2011
87 The Impact of Pre-Formed Donor-Specific HLA Antibodies on Early Clinical Outcomes in Lung Transplant Recipients
Fujimoto K, Shigemura N, Sareyyupoglu B, Bansal A, Minakata K, Shayan H, Ota T, Bhama J, Bonde P, Thacker J, Bermudez C, Zaldonis D, Zeevi A, Toyoda Y. 87 The Impact of Pre-Formed Donor-Specific HLA Antibodies on Early Clinical Outcomes in Lung Transplant Recipients. The Journal Of Heart And Lung Transplantation 2011, 30: s37. DOI: 10.1016/j.healun.2011.01.094.Peer-Reviewed Original ResearchPrimary graft dysfunctionMean fluorescent intensityAcute cellular rejectionEarly clinical outcomesClinical outcomesDSA groupDonor selectionSurvival rateDonor-specific HLA antibodiesClass II DSALung transplant recipientsPrimary graft failureLung transplant candidatesHLA-specific antibodiesLevels of AbsCellular rejectionGraft dysfunctionLTx candidatesLTx groupProspective crossmatchHLA antibodiesLung transplantTransplant recipientsDepletion therapyGraft failure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply